Viewing Study NCT04139902


Ignite Creation Date: 2025-12-25 @ 3:52 AM
Ignite Modification Date: 2025-12-26 @ 2:41 AM
Study NCT ID: NCT04139902
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-15
First Post: 2019-10-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
Sponsor: Diwakar Davar
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module